<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28445307</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1536-5964</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>17</Issue><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Medicine</Title><ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation></Journal><ArticleTitle>Alteration of serum high-mobility group protein 1 (HMGB1) levels in children with enterovirus 71-induced hand, foot, and mouth disease.</ArticleTitle><Pagination><StartPage>e6764</StartPage><MedlinePgn>e6764</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e6764</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000006764</ELocationID><Abstract><AbstractText>Hand, foot, and mouth disease (HFMD) is a common pediatric disease caused by enterovirus infection. It typically presents as a fever along with flat, discolored spots and bumps on the hands, feet, and mouth. Compared with other viruses, enterovirus 71 (EV71)-induced HFMD is more prone to cause severe complications in children, such as brainstem encephalitis, cardiopulmonary disorders, and even death. More in-depth studies are still necessary to understand the characteristics of EV71-induced HFMD, although some related research has been reported so far. High-mobility group box 1 (HMGB1) is an inflammatory cytokine that can upregulate other inflammatory factors through its receptors, such as Toll-like receptors and the receptor for advanced glycation endproducts.We prospectively investigated the alteration of serum HMGB1, interleukin (IL)-6, and tumor necrosis factor (TNF)-&#x3b1; levels before and after treatment in 82 children with HFMD.We found that the serum HMGB1, IL-6, and TNF-&#x3b1; levels were significantly increased in EV71-induced HFMD, and that these changes were more serious in the severe and critical HMFD groups; however, there was no significant difference in the HMGB1 level between the normal control and mild HMFD groups. Moreover, the serum HMGB1 level was positively correlated with the alteration of serum IL-6 and TNF-&#x3b1; concentrations.These results suggest that HMGB1 is involved in the inflammatory pathogenesis of EV71-induced HFMD and that the serum level of HMGB1 could be applied as a clinical indicator for the severity of HFMD, and also a sign for the recovery prognosis of HFMD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Weikun</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Childhood Infectious Diseases, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Haifan</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Longteng</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Medicine (Baltimore)</MedlineTA><NlmUniqueID>2985248R</NlmUniqueID><ISSNLinking>0025-7974</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C585491">HMGB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001774" MajorTopicYN="N">Blood Chemical Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006232" MajorTopicYN="N">Hand, Foot and Mouth Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>4</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28445307</ArticleId><ArticleId IdType="pmc">PMC5413272</ArticleId><ArticleId IdType="doi">10.1097/MD.0000000000006764</ArticleId><ArticleId IdType="pii">00005792-201704280-00056</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol 2010;9:1097&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PC, Chen SC, Chen KT. The current status of the disease caused by Enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health 2016;13:890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036723</ArticleId><ArticleId IdType="pubmed">27618078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KY. Enterovirus 71 infection and neurological complications. Korean J Pediatr 2016;59:395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Hsia SH, Huang YC, et al. Proinflammatory cytokine reactions in enterovirus 71 infections of the central nervous system. Clin Infect Dis 2003;36:269&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12539066</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev 2005;15:496&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">16102963</ArticleId></ArticleIdList></Reference><Reference><Citation>Oozawa S, Mori S, Kanke T, et al. Effects of HMGB1 on ischemia-reperfusion injury in the rat heart. Circ J 2008;72:1178&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">18577832</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims GP, Rowe DC, Rietdijk ST, et al. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2009;28:367&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">20192808</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011;29:139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4536551</ArticleId><ArticleId IdType="pubmed">21219181</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803152</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang PN, Shih SR. Update on enterovirus 71 infection. Curr Opin Virol 2014;5:98&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">24727707</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, Wei D, Ou W-L, et al. Autopsy findings in children with hand, foot, and mouth disease. N Engl J Med 2012;367:91&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">22762340</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Ward MF, Fan X-G, et al. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006;19:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1782047</ArticleId><ArticleId IdType="pubmed">16553546</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Yue Y, Dong C, et al. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis. Clin Vaccine Immunol 2013;20:1743&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837774</ArticleId><ArticleId IdType="pubmed">24027262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">10398600</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012;8:195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">22293756</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4533842</ArticleId><ArticleId IdType="pubmed">19948257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichiyama T, Nishikawa M, Yoshitomi T, et al. Tumor necrosis factor-a, interleukin-l&#x3b2;, and interleukin-6 in cerebrospinal fluid from children with prolonged febrile seizures: comparison with acute encephalitis/encephalopathy. Neurology 1998;50:407&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9484363</ArticleId></ArticleIdList></Reference><Reference><Citation>Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signaling. Mol Med 2008;14:476.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2323334</ArticleId><ArticleId IdType="pubmed">18431461</ArticleId></ArticleIdList></Reference><Reference><Citation>Troseid M, Sonnerborg A, Nowak P. High mobility group box protein-1 in HIV-1 infection: connecting microbial translocation, cell death and immune activation. Curr HIV Res 2011;9:6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">21198433</ArticleId></ArticleIdList></Reference><Reference><Citation>Allonso D, Belgrano FS, Calzada N, et al. Elevated serum levels of high mobility group box 1 (HMGB1) protein in dengue-infected patients are associated with disease symptoms and secondary infection. J Clin Virol 2012;55:214&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22884669</ArticleId></ArticleIdList></Reference><Reference><Citation>Nosaka N, Yashiro M, Yamada M, et al. Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice. Crit Care 2015;19:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4490661</ArticleId><ArticleId IdType="pubmed">26067826</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangert A, Andrassy M, M&#xfc;ller A-M, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci 2016;113:E155&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4720305</ArticleId><ArticleId IdType="pubmed">26715748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaya Z, G&#xf6;ser S, Buss SJ, et al. Identification of cardiac troponin I sequence motifs leading to heart failure by induction of myocardial inflammation and fibrosis. Circulation 2008;118:2063&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774217</ArticleId><ArticleId IdType="pubmed">18955666</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzo M, Molteni R, Suda T, et al. Inhibitor of NK-kB Kinases a and b are both essential for high mobility group box 1-mediated chemotaxis. J Immunol 2010;184:4497&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2915896</ArticleId><ArticleId IdType="pubmed">20231695</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>